Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

(2019) Miguel A. Sanz et al.   BLOOD

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial

(2019) Laura Cicconi et al.   LEUKEMIA

Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial

(2018) Hong-Hu Zhu et al.   LANCET ONCOLOGY

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

(2017) Uwe Platzbecker et al.   JOURNAL OF CLINICAL ONCOLOGY

The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia

(2016) H. Zhu et al.   BLOOD

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

(2016) Yasmin Abaza et al.   BLOOD

All-trans retinoic acid and arsenic combination therapy benefits low-to-intermediate-risk patients with newly diagnosed acute promyelocytic leukaemia: a long-term follow-up based on multivariate analysis

(2015) Hongming Zhu et al.   BRITISH JOURNAL OF HAEMATOLOGY

Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer

(2015) J.-Q. Mi et al.   JOURNAL OF INTERNAL MEDICINE

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

(2015) Alan K Burnett et al.   LANCET ONCOLOGY

Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide

(2015) Yang Shen et al.   EBioMedicine

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

(2013) Francesco Lo-Coco et al.   NEW ENGLAND JOURNAL OF MEDICINE

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

(2012) H. J. Iland et al.   BLOOD

How to manage acute promyelocytic leukemia

(2012) J-Q Mi et al.   LEUKEMIA

Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial

(2012) A K Burnett et al.   LEUKEMIA

Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia

(2011) Ardeshir Ghavamzadeh et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

(2010) M. A. Sanz et al.   BLOOD

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

(2010) F. Lo-Coco et al.   BLOOD

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

(2010) B. L. Powell et al.   BLOOD

Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia

(2010) Steven D. Gore et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data

(2010) Vikram Mathews et al.   JOURNAL OF CLINICAL ONCOLOGY

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG

(2009) E Lengfelder et al.   LEUKEMIA

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

(2009) J. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acute promyelocytic leukemia: from highly fatal to highly curable

(2008) Z.-Y. Wang et al.   BLOOD

Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

(2008) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY